SCHEMBL1018243

SCHEMBL1018243

COCCN(C)c1ccc2c(n1)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.41
HRH3 Q9Y5N1 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 2/20 0.36
PARP1 P09874 1/20 0.35
MTNR1B P49286 1/20 0.35
BDKRB1 P46663 4/20 0.34
F10 P00742 1/20 0.34
KDM4E B2RXH2 2/20 0.34
FFAR1 O14842 1/20 0.33
CFTR P13569 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016464 0.88 PARP1 (0.37) HRH3ALDH1A1KMT2ATSHRPARP1
SCHEMBL1070174 0.87 PARP1 (0.39) HRH3ALDH1A1KMT2ATSHRPARP1
SCHEMBL1018115 0.87 ADRA1A (0.38) ADRA1AALDH1A1KMT2AFFAR1CFTR
SCHEMBL12707161 0.87 ADRA1A (0.38) ADRA1AALDH1A1KMT2AFFAR1CFTR
SCHEMBL1018061 0.87 PARP1 (0.36) HRH3ALDH1A1KMT2ATSHRPARP1
SCHEMBL1603356 0.85 PARP1 (0.35) HRH3ALDH1A1KMT2ATSHRPARP1
SCHEMBL1018889 0.84 PARP1 (0.41) HRH3ALDH1A1KMT2ATSHRPARP1
SCHEMBL1018492 0.82 ADRA1A (0.43) ADRA1AHRH3ALDH1A1KMT2ATSHR
SCHEMBL1016337 0.80 ADRA1A (0.39) ADRA1AHRH3ALDH1A1KMT2ATSHR
SCHEMBL1015743 0.80 HRH3 (0.44) HRH3ALDH1A1KMT2ATSHRPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ADRA1A 381/4885HRH3 1/4885ALDH1A1 1229/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ADRA1A 381/4885HRH3 1/4885ALDH1A1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.